Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 9/20 | 0.54 |
| ▸ | FNTB | P49356 | 9/20 | 0.54 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | FPR1 | P21462 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18106731 | 1.00 | FNTA (0.54) | FNTAFNTBPGGT1BLTA4HFPR1 | |
| SCHEMBL30051234 | 0.91 | FNTA (0.58) | FNTAFNTBPGGT1BLTA4H | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL17202476 | 0.89 | FPR1 (0.61) | LTA4HFPR1FPR2MME | |
| Phenylalanine SCHEMBL304849 | 0.89 | LTA4H (0.50) | FNTAFNTBPGGT1BLTA4HFPR1 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39528 | 0.89 | FPR1 (0.61) | LTA4HFPR1FPR2MME | |
| Dl-Phenylalanine SCHEMBL7222094 | 0.89 | LTA4H (0.50) | FNTAFNTBPGGT1BLTA4HFPR1 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL4592799 | 0.89 | FPR1 (0.61) | LTA4HFPR1FPR2MME | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39529 | 0.89 | FPR1 (0.61) | LTA4HFPR1FPR2MME | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL9903983 | 0.89 | FPR1 (0.61) | LTA4HFPR1FPR2MME | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL4969844 | 0.89 | FPR1 (0.61) | LTA4HFPR1FPR2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250157661-A1 | MONITORING INFLAMMATION STATUS | MOLOGIC LIMITED (GB) | 2025-05-15 | — | — | US | disclosed |
| EP-4396229-A1 | ANTI-CECAM6 ANTIBODIES WITH REDUCED SIDE-EFFECTS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2024-07-10 | — | — | EP | disclosed |
| EP-4381064-A1 | COMPOUND AND METHOD FOR A SPECIFIC TARGETING OF THE HAXI GENE | Eberhard Karls Universität Tübingen, Medizinische Fakultät (DE) | 2024-06-12 | — | — | EP | disclosed |
| EP-4376837-A1 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | Immunyx Pharma Ltd. (IL) | 2024-06-05 | — | — | EP | disclosed |
| EP-4347128-A2 | METHOD AND SYSTEM FOR SINGLE-CELL BIOPHYSICAL PROFILING USING A MICROFLUIDIC DEVICE | Nanyang Technological University (SG) | 2024-04-10 | — | — | EP | disclosed |
| US-20240101618-A1 | IMMUNOMODULATORY PEPTIDE | INSTITUT NATIONAL UNIVERSITAIRE JEAN-FRANCOIS CHAMPOLLION (FR) | 2024-03-28 | — | — | US | disclosed |
| WO-2024028436-A1 | NOVEL INTERLEUKIN-17A (IL-17A)-DERIVED PEPTIDE AND NEUTRALIZING ANTIBODY (AB17-IPL-1) | THE UNIVERSITY OF BIRMINGHAM (GB) | 2024-02-08 | — | — | WO | disclosed |
| US-20240024473-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4259776-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | Purdue Research Foundation (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11753452-B2 | Immunomodulatory peptide | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | 2023-09-12 | — | — | US | disclosed |
| US-7842795-B2 | Gene sequence coding formyl peptide receptor binding protein; diagnosing cancer, wound bone healing, obesity, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, restenosis, atherosclerosis, thrombosis, cardiovascular, autoimmune and nervous system disorders | EUROSCREEN S.A. (BE) | 2010-11-30 | — | — | US | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
| EP-1607745-B1 | Ligand for G-protein coupled receptor FPRL2 and uses thereof | EUROSCREEN SA (BE) | 2010-02-24 | — | — | EP | disclosed |
| US-7659251-B2 | Ligand for G-protein coupled receptor FPRL2 | OGEDA SA (BE) | 2010-02-09 | — | — | US | disclosed |
| US-20100009406-A1 | Nucleic acids encoding a heme binding protein polypeptide | OGEDA SA (BE) | 2010-01-14 | — | — | US | disclosed |
| US-7582416-B2 | Detecting of formyl peptide receptor like-2 (FPRL2) polypeptide activity using a heme binding protein (HBP) polypeptide as a modulating agents of polypeptide activity;. antibodies against FPRL2; drug screening for treating diseases characterized by dysregulation of FPRL2 polypeptide signal transduction | OGEDA SA (BE) | 2009-09-01 | — | — | US | disclosed |
| US-20090053739-A1 | Ligand for G-protein coupled receptor FPRL2 and uses thereof | OGEDA SA (BE) | 2009-02-26 | — | — | US | disclosed |
| EP-2020604-A1 | Ligand for G-protein coupled receptor FPRL2 and uses thereof | Euroscreen S.A. (BE) | 2009-02-04 | — | — | EP | disclosed |
| US-20060078559-A1 | Ligand for G-protein coupled receptor FPRL2 and uses thereof | OGEDA SA (BE) | 2006-04-13 | — | — | US | disclosed |
| EP-1607745-A2 | Ligand for G-protein coupled receptor FPRL2 and uses thereof | Euroscreen S.A. (BE) | 2005-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024473-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PBK, KIT, MYD88 | FNTA 3635/4885FNTB 3019/4885PGGT1B 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.